Juvaris BioTherapeutics has announced the signing of an agreement with Antigen Discovery to access Antigen’s high-throughput protein microarray screening system to discover novel immunodominant disease-specific antigens. Juvaris will sponsor research for multiple disease targets and pay Antigen upfront payments, development milestones and royalties on licensed products in exchange for full product development rights to all fields except diagnostics, which will belong to Antigen. In March 2008 Juvaris signed a collaboration agreement with the Animal Health Division of Bayer HealthCare AG.
June 30, 2009...8:53 am
Juvaris BioTherapeutics signs collaboration agreement with Antigen Discovery
Jump to Comments
